PEcoma市場：現況分析與預測（2023-2030）

2022年PEcoma城市成長率4,550萬米元，節省2023年至2030年年複合成長率5%。

依類型分類、市場分類、診斷及治療。 2022年，市場將以治療類型為主導。 在治療選擇上，手術是主要的治療選擇，特殊治療是局部疾病。 手術徹底切除是目標，因此有可能顯著改善患者的病情。 然而，根據夜間的時間段，手術的效果會受到限制。 因此，對於未經有效治療就無法切除或轉移的PEcoma的治療材料的需求持續增加。

最終使用部門、市場部門醫院、醫療中心等 其中，2022年主要市價依醫院類型劃分。 主要原因是手術治療先進，醫院擁有先進的醫療設備和專業知識。

業務市場介紹，將市場劃分：北碚（Mikuni、加拿大大學、北碚等地區）、Pershu（Tokkoku、英國、Hokoku、Eidali、Xibanga、Pershu等地區）、亞太地區（中國、日本）、印度、韓國、澳門等）等世界各地。 到2022年，PEcoma市場的價格將會上漲。 推動北美市場成長的主要因素是各國基礎醫療設施的擴張以及醫療衛生支出的增加。

我錄

第一章市場介紹

• 市場定義
• 主要目標
• 有興趣的人
• 有限

第 2 章研究方法/建立

• 調查過程
• 調查方法
• 訪客簡報

第三章市場對接

第四章執行總結

第五章新型冠狀病毒感染 (COVID-19) 對全球 PEcoma 市場的影響

第 6 章 2020-2030 年全球 PEcoma 市場進入

第七章分類市場洞察

• 考試
• 作弊
  • 化療
  • 火車治療
  • 放射治療
  • 其他

第 8 章最終用戶市場洞察

• 醫院
• 臨床檢驗中心
• 其他

第 9 章區域市場洞察

• Kitabi PEcoma 市場
  • 三國
  • 加那大學
  • 北見其他地區
• 九州PEcoma市場
  • 德國
  • 英語
  • 北國
  • 巨大的好處
  • 西番賀
  • 其他九州地區
• 艾泰區PEcoma市場
  • 中國
  • 日本
  • 印度
  • 亞洲其他國家/地區
• 其他地區 PEcoma 市場

第 10 章 PEcoma 市場動態

• 市場驅動因素
• 市場挑戰
• 影響分析

第 11 章 PEcoma 市場機會

第十二章 PEcoma 市場趨勢

第十三章供給與需求方法分析

• 需求分析
• 供給面分析

第14章分析

第 15 章賽道視圖

• 競爭狀況
  • Hatoku 五力分析

第十六章公司摘要

• Sarcoma Oncology Research Center LLC
• Aadi Bioscience Inc
• Novartis Pharmaceuticals
• CENTOGENE GmbH Rostock
• Antia Therapeutics AG
• InCor Heart Institute
• Children's Hospital Medical Center
• Johnson & Johnson
• Pfizer
• Mylan N.V.

第十七章免責聲明

Perivascular epithelioid cell tumors, also known as PEComa, represent a rare type of mesenchymal neoplasm that originates from perivascular epithelioid cells. These tumors can occur in various organs throughout the body, such as the uterus, kidney, liver, and gastrointestinal tract. PEComa is considered a challenging disease due to its rarity and the limited understanding surrounding its pathogenesis. Further, continuous rise in the incidences of Pecoma is also driving the market. For instance, as per the National Organization for Rare Disorders, Malignant PEComas are estimated to be diagnosed in 0.12 to 0.24 per one million people.

The PEcoma market was valued at USD 45.5 million in 2022 and is expected to grow at a CAGR of around 5% from 2023-2030.

Based on the type, the market is segmented into diagnosis and Treatment. The treatment category dominated the market in 2022. Regarding therapeutic options, surgery is the primary treatment modality for PEComa, particularly for localized disease. Complete surgical resection is the aim, as it significantly improves patients' outcomes. However, the effectiveness of surgery in advanced or metastatic cases is limited. Thus, there is a growing demand for targeted therapies that can effectively treat unresectable or metastatic PEComa.

On the basis of end-users, the market is categorized into Hospitals, diagnostic centers, and Others. Among these, the hospital's category held a significant market share in 2022. This is mainly due to the high volume of PEcome surgeries and treatments performed in hospitals, as well as the availability of advanced medical equipment and expertise in this setting.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America held dominating share of PEcoma market in 2022. The presence of well-established healthcare infrastructure, along with the increasing healthcare expenditure in the countries is the major attributing factor for the market growth in North America.

Some of the major players operating in the market include: Sarcoma Oncology Research Center LLC, Aadi Bioscience Inc, Novartis Pharmaceuticals, CENTOGENE GmbH Rostock, Antia Therapeutics AG, InCor Heart Institute, Children's Hospital Medical Center, Johnson & Johnson, Pfizer, and Mylan N.V.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the PEcoma Market
• 2.2. Research Methodology of the PEcoma Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL PECOMA MARKET COVID-19 IMPACT

6 GLOBAL PECOMA MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY TYPE

• 7.1. Diagnosis
• 7.2. Treatment
  • 7.2.1. Chemotherapy
  • 7.2.2. Targeted Therapy
  • 7.2.3. Radiotherapy
  • 7.2.4. Others

8 MARKET INSIGHTS BY END USER

• 8.1. Hospitals
• 8.2. Diagnostic Centers
• 8.3. Others

9 MARKET INSIGHTS BY REGION

• 9.1. North America PEcoma Market
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe PEcoma Market
  • 9.2.1. Germany
  • 9.2.2. UK
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific PEcoma Market
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of APAC
• 9.4. Rest of the World PEcoma Market

10 PECOMA MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 PECOMA MARKET OPPORTUNITIES

12 PECOMA MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1. Demand Side Analysis
• 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

• 15.1. Competitive Landscape
  • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

• 16.1. Sarcoma Oncology Research Center LLC
• 16.2. Aadi Bioscience Inc
• 16.3. Novartis Pharmaceuticals
• 16.4. CENTOGENE GmbH Rostock
• 16.5. Antia Therapeutics AG
• 16.6. InCor Heart Institute
• 16.7. Children's Hospital Medical Center
• 16.8. Johnson & Johnson
• 16.9. Pfizer
• 16.10. Mylan N.V.

17 DISCLAIMER